Digital Trials Digest, our quarterly newsletter
Capturing and assessing patient-reported outcomes is key to driving patient centricity in healthcare research and delivery. However, the life sciences industry has frequently struggled to gather adequate, high-quality participant data in clinical trials, resulting in costly delays for study teams.
In this post, we provide a comprehensive breakdown of the key challenges and opportunities associated with virtual clinical trials, examining the nuances of virtual components and how their implementation might affect each stage and touchpoint of the clinical trial journey.
Clinical trial sponsors are constantly seeking ways to collect better data, faster—accelerating clinical trials. Meanwhile, patients are increasingly likely to access healthcare services and interact with healthcare professionals digitally. Growing usage of telehealth also impacts patients’ expectations of clinical trials, with convenience and accessibility taking center stage.
Hybrid clinical trials drive efficiency, engagement, and effectiveness in clinical research. See whether a hybrid model could be a fit for your upcoming study.
ObvioHealth highlight the benefits of incorporating DCTs, as well as the challenges associated with DCTs, and call out specific use cases for DCTs.
In three short years, decentralized clinical trials (DCTs) have turned skeptics into believers. Trial sponsors who were once hesitant are now embracing the DCT model—and for good reason. Today’s DCTs are addressing longstanding industry challenges, expanding access to patients and clinicians, increasing diversity, accelerating cohort recruitment, and improving retention.
When it comes to decentralized clinical trials (DCTs), the pharmaceutical industry finds itself at a crossroads.
For patients with rare, incurable, or life-threatening diseases, clinical trials can offer new hope. Cancer patients, specifically, are often highly motivated to participate in research, particularly when they have an advanced or treatment-resistant form of cancer. Find out how decentralized clinical trials reach patients in the comfort of their homes.
While there's broad agreement on the gap between white and non-white participation in clinical trial enrollment, the number of non-white patients enrolled in clinical trials for general population studies is still quite low. But why?
Digital instruments such as sensors and wearables are transforming the industry’s definition of accuracy in three measures: volume, practicality, and precision.